$AZN $MRK The FDA approved selumetinib (branded Koselugo) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1). #RareDiseases

SAEs include heart failure and ocular toxicity; drug can increase CPK levels.

https://t.co/yvKazjbXhS